Canada has never recorded a single Ebola case, yet Nova Scotia is now home to the world’s first human trial of a new Ebola vaccine — and there’s a very specific reason it was chosen.
The first participant in a new Ebola vaccine trial received their shot in Truro, Nova Scotia, on 4 August 2026 — a distinctive choice, given Ebola has never once been detected in Canada. Health Canada authorised the Phase 1 clinical trial on 30 July, making Canada the first country in the world to test Moderna’s mRNA-1469 vaccine in humans. (1✔ ✔Trusted Source
Why Nova Scotia was chosen to test a new Ebola vaccine
)
Advertisement
What Country Created the Ebola Vaccine?
This isn’t Canada’s first connection to Ebola vaccine research. The world’s only currently licensed Ebola vaccine, Ervebo, was originally engineered by scientists at the Public Health Agency of Canada’s National Microbiology Laboratory in Winnipeg, before Merck licensed and developed it further, securing FDA approval in December 2019. Ervebo protects specifically against the Zaire strain of Ebola — one of four species that can cause severe disease in humans. (2✔ ✔Trusted Source
Health Canada authorizes vaccine clinical trial for Ebola disease caused by the Bundibugyo virus
)
Moderna’s Hamilton Bennett, the company’s executive director of health security research and development, said Canada was selected this time based on “the country’s long-standing contributions to filovirus research,” alongside Health Canada’s regulatory oversight and Moderna’s prior experience working with Canadian trial sites.
Advertisement
What Is Canada Doing About the Ebola Virus?
While Canada carries no outbreak risk itself, it’s playing a direct role in the global response to one. The trial is running across three Canadian sites — Truro and Halifax in Nova Scotia, and Toronto.
Roughly 80 healthy adult volunteers have enrolled for the traial. None will be exposed to the virus; the goal is purely to test the vaccine’s safety, correct dosing, and immune response. (3✔ ✔Trusted Source
A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in Healthy Adult Participants
Scott Halperin, the Halifax trial’s principal investigator and a Dalhousie University professor, said volunteers are motivated by more than curiosity: “People are very altruistic… even though it’s not a risk to them and likely never will be, people are still interested in volunteering in order to contribute to developing vaccines that are going to save lives elsewhere.”
Advertisement
Why Is There Urgency Around This Trial?
The vaccine targets the Bundibugyo strain of Ebola — a form with no existing licensed vaccine — currently driving what the World Health Organization describes as the second deadliest Ebola outbreak on record.
The outbreak was first declared on 15 May 2026 in the Democratic Republic of the Congo and has since spread into Uganda, with more than 3,700 confirmed cases and over 1,650 deaths recorded as of 1 August across 49 health zones in five provinces.
Moderna’s candidate is one of four Bundibugyo vaccine candidates now being developed in parallel using different technologies, in a race to find an effective option as quickly as possible. The UK has also begun a separate trial of its own Bundibugyo candidate, developed by the University of Oxford.
Is There a Vaccine for Ebola? What This Trial Actually Tests
This is a Phase 1 trial, meaning it assesses safety and dosing, not real-world effectiveness. Participants will be closely monitored for the first week, with ongoing monitoring continuing for a full year to track any long-term effects. Should the vaccine clear this phase, later trial stages are planned to take place in or near the actual outbreak zone in East Africa, where efficacy against real infection can eventually be studied.
Volunteers are being recruited through social media, a dedicated trial website, and a database of past participants, and typically receive a modest payment — usually between $50 and $100 — for their time.
The Bottom Line
A country with zero Ebola cases is now at the centre of the global effort to stop one of its deadliest outbreaks — not despite that fact, but partly because of Canada’s decades-long, lower-profile history in filovirus research.
If mRNA-1469 succeeds, the strain currently devastating The Democratic Republic of Congo (DRC) and Uganda could finally get what the Zaire strain already has: a proven vaccine.
References:
- Why Nova Scotia was chosen to test a new Ebola vaccine – (https://www.cbc.ca/news/canada/nova-scotia/why-nova-scotia-was-chosen-to-test-new-ebola-vaccine-9.7299588)
- Health Canada authorizes vaccine clinical trial for Ebola disease caused by the Bundibugyo virus – (https://www.canada.ca/en/health-canada/news/2026/08/health-canada-authorizes-vaccine-clinical-trial-for-ebola-disease-caused-by-the-bundibugyo-virus.html)
- A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in Healthy Adult Participants – (https://trials.modernatx.com/study/?id=mRNA-1469-P101)
Source-CBC News, Health Canada, Moderna